IMPORTANT INFORMATION
Specimens and Orders for BarreGEN® Are No Longer Being Accepted
BarreGEN® utilizes PathFinderTG®, a proprietary DNA-based diagnostic molecular testing platform used by Interpace Diagnostics® within their PancraGEN® and BarreGEN testing services to identify tumor suppressor gene and oncogene mutations within GI specimens.
Novitas Solutions, the Medicare Administrative Contractor for Interpace, has issued a Local Coverage Decision (L39365) that ended reimbursement for PancraGEN.
Because PancraGEN comprised the vast majority of GI-related testing within Interpace and is primarily ordered for Medicare patients, this change in the reimbursement policy means that Interpace Diagnostics can no longer support utilization of the PathFinderTG platform and testing of esophageal specimens with BarreGEN.
Specimens and orders for BarreGEN are no longer being accepted as of
May 30, 2025*
Interpace will continue to offer ThyGeNEXT®+ThyraMIR®v2 without interruption.
Questions regarding this announcement can be addressed by contacting Interpace Client Services.
(800) 495‑9885 or clientservices@interpace.com
*The last shipping date using FedEx Priority Overnight is Thursday May 29th (ensure the FedEx pickup time cutoff is met).
